Code | 8389D | ||||||||||
MA number | 59/0321/18-S | ||||||||||
Product Form: | cps dur 7(7x1)x10 mg (blis.OPA/Al/PVC/Al - perfor.blister) | ||||||||||
MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
Type of procedure: | Decentralised | ||||||||||
MAH, country: | Sandoz Pharmaceuticals d.d., Slovenia | ||||||||||
Therapeutic Class: | 59 - IMMUNOPRAEPARATA | ||||||||||
ATC: |
|
||||||||||
Shelf life: | 36 | ||||||||||
Container: | blister OPA/Al/PVC/Al | ||||||||||
Route of admin.: | Oral use |
Prescription Status: | Medicinal product subject to restricted medical prescription. |
Legal basis: | Article 10(1) generic application |
MA issued: | 27.09.2018 |
PIL: | PIL_Lenalidomid_Sandoz_10 mg_15 mg_25 mg_11.2023.pdf |
Dokument: | Lenalidomid_Sandoz_Príručka_pre_pacienta.pdf |
Dokument: | Lenalidomid_Sandoz_Príručka_pre_zdravotníckych_pracovníkov.pdf |
Dokument: | Lenalidomid_Sandoz_Sprievodca_pri_predpisovaní.pdf |
Dokument: | Lenalidomid_Sandoz_Súhrnný_kontrolný_zoznam.pdf |
Dokument: | Lenalidomid_Sandoz_Informačný_balík_pre_zdravotníckych pracovníkov.pdf |
Dokument: | Lenalidomid_Sandoz_Často_kladené_otázky.pdf |
Dokument: | Lenalidomid_Sandoz_Karta_pacienta.pdf |
SPC: | SPC_Lenalidomid Sandoz_10 mg_15 mg_25 mg_07.2024.pdf |
Safety feature | Yes |
Data update: | 24.04.2023 |